

# Progress in silk and silk fiber-inspired polymeric nanomaterials for drug delivery

Marisa O Pacheco<sup>1</sup>, Lauren E Eccles<sup>1</sup>, Nickolas A Davies<sup>2</sup>, Jostin Armada<sup>1</sup>, Alaura S Cakley<sup>1</sup>, Isiri P Kadambi<sup>1</sup>, Whitney L Stoppel<sup>1\*</sup>

<sup>1</sup>Department of Chemical Engineering, Herbert Wertheim College of Engineering, University of Florida, Gainesville, FL

<sup>2</sup>College of Medicine, University of Florida, Gainesville, FL

\*Corresponding Author:

[whitney.stoppel@ufl.edu](mailto:whitney.stoppel@ufl.edu)

Department of Chemical Engineering  
1030 Center Drive  
PO Box 116005  
Gainesville, FL 32611

## Abstract


The fields of drug and gene delivery have been revolutionized by the discovery and characterization of polymer-based materials. Polymeric nanomaterials have emerged as a strategy for targeted delivery because of features such as their impressive biocompatibility and improved availability. Use of naturally derived polymers in these nanomaterials is advantageous due to their biodegradability and bioresorption. Natural biopolymer-based particles composed of silk fibroins and other silk fiber-inspired proteins have been the focus of research in drug delivery systems due to their simple synthesis, tunable characteristics, and ability to respond to stimuli. Several silk and silk-inspired polymers contain a high proportion of reactive side groups, allowing for functionalization and addition of targeting moieties. In this review, we discuss the main classes of silk and silk-inspired polymers that are being used in the creation of nanomaterials. We also focus on the fabrication techniques used in generating a tunable design space of silk-based polymeric nanomaterials and detail how that translates into use for drug delivery to several distinct microenvironments.

**Keywords:** polymeric nanoparticles, natural biopolymers, silk, drug delivery, nanomaterials

## Introduction

The efficacy of treatment for numerous diseases and conditions including, but not limited to, cancers, autoimmune disorders, inflammation, and infection, is limited by how therapeutic agents and drugs are delivered. Systemically administered drugs suffer from low water solubility, rapid clearance, and can cause a variety of off-target side effects (1). Administering drugs via alternative routes is an area of interest, but overcoming the body's natural barrier systems is a significant challenge. To address the limitations associated with systemic delivery, research focused on advanced drug delivery systems (DDS) has been a major area of interest (2). Nanomaterial-based DDS, such as nanoparticles, liposomes, and dendrimers, have been shown to enhance the bioavailability of various therapeutics (3, 4). A major class of nanomaterial DDS are polymeric nanomaterials engineered to include features such as targeting moieties (5). Using natural biopolymers for the creation of these DDS is further advantageous due to their impressive biocompatibility and biodegradability (6). The main classes of natural biopolymers used for the synthesis of nanoparticle-based systems are polysaccharides and proteins.

Silk fibroins and other silk fiber-inspired proteins have been shown to be biocompatible and easily digested by immune cells and proteolytic enzymes into products that can re-enter native metabolic processes on a tunable timeline (7, 8). Apart from their biocompatibility and tunable biodegradation, silk proteins are also advantageous polymers for the engineering of DDS due to the myriad of methods to induce increases in crystalline content. This translates into numerous methods for engineering nanomaterials of various sizes, depending on the end state application, that don't require the use of harsh solvents (9). Increased crystalline content also limits the tendency for burst release behavior (9, 10). The main silk proteins that have been explored for use in a variety of nanoparticle DDS are silk fibroins from the *Bombyx mori* silkworm. *Bombyx mori* silk fibroin is the most well-characterized silk protein source and has a variety of reactive amino acids to allow for functionalization (11-15). Other silk proteins, including *Bombyx mori*



**Figure 1:** Common methods for silk biopolymer fabrication and functionalization.

sericin, genetically engineered silk fibroin proteins, silk fibers from other *Antheraea* species, and bioengineered spider fibroin silks (12), are being explored due to their enhanced ability for functionalization, potential for a wider range of material and mechanical properties, and increased homogeneity of the starting polymer. In this review, we discuss the primary structure of these silk proteins and relate the structure to fabrication strategies for nanomaterials (**Figure 1**). We also highlight progress in the *in vitro* and *in vivo* evaluations of silk-based DDS.

## Fabrication and evaluation of nanomaterial DDS based on silk proteins and silk fiber-inspired polymers

### *Bombyx mori* fibroin

*Bombyx mori* silk is composed of two main protein groups, fibroin and sericin. Two fibroin fibers are surrounded by a sericin coating. When fibroin and sericin are present together, there is decreased biocompatibility (16). Sericin is water soluble, allowing for fibroin to be readily extracted (17). Historically, sericin has been discarded as waste, but we discuss the potential for sericin nanomaterials in a later section.

Fibroin from *Bombyx mori* is biocompatible and the focus of biomedical research for applications including nanomaterials and both local and systemic DDS. Fibroin consists of heavy (~325 kDa) and light (~26 kDa) chains linked with a disulfide bond (18). The light chain is elastic, hydrophilic, and characterized by nonrepeating sequences of amino acids. The heavy chain comprises highly hydrophobic and crystalline motifs (GAGAGS or GAGAGX, X=V or Y) separated by amorphous regions containing polar and charged amino acids (18). The hydrophobic motifs can form layers of beta-sheet structures, thereby altering the crystallinity and mechanical properties of fibroin-based materials. The level of crystallinity varies with the material fabrication methods and can be further increased using post-processing techniques such as water annealing (7, 17, 19). Fibroin nanoparticles have also been shown to have stimuli-responsive behavior, with increased degradation and drug release occurring as a function of stimuli such as pH and the presence of reactive oxygen species, making them advantageous for delivery of therapies like chemotherapeutics (20-22).

To form nanomaterials with silk fibroin, researchers have developed an array of physical and chemical methods to induce the hydrophobic collapse of the hydrophobic motifs and encourage the formation of water insoluble nanoparticles (13-15, 23, 24). Recent studies have utilized techniques such as spray drying (25), organic solvent desolvation (21, 26, 27), salting out (28), and microfluidic devices (29-33) (**Table 1**). Control of particle size and material properties to enhance cell material interaction (34) and to optimize non-systemic delivery routes has been established (35-38).

Recently, researchers have combined functionalization techniques with the use of composite materials to generate the next generation of silk-based nanomaterials that can function as targeted delivery systems (26, 28, 39-44) and as systems for both therapy and diagnostics (45-

47). Pham et al. developed a fibroin nanoparticle system for delivery of therapeutics in the treatment of colon cancer (43). They encapsulated paclitaxel in fibroin particles (300-500 nm) formed by organic solvent desolvation and EDC crosslinking. They found their formulations were effective in colon and breast cell cancer lines, but interestingly observed that when the formulation was used in colon cancer lines, cytotoxic efficiency increased 10-fold relative to free drug (43). Du et al. also explored targeting sites in the colon for ulcerative colitis (42). They formed nanoparticles by desolvation and then surface functionalized them with cRGD. Safety and efficacy were evaluated *in vitro* and *in vivo* and it was found that the cRGD functionalized particles specifically interacted with integrin  $\alpha_v$  inflammation sites in the colon and contributed to an improved therapeutic outcome (42). Horo et al. developed a composite material for targeted delivery of antitumor agents (41). They developed chitosan-stabilized gold nanoparticles (~8 nm) loaded with doxorubicin and coated with fibroin conjugated with folic acid and fluorescein to promote the targeting of tumor cells. The silk coating contributed to an improved drug release profile and increased uptake and cytotoxicity in HeLa cultures. They also modified this formulation into larger particles (~1000  $\mu$ m) using ionic gelation to address the potential for oral delivery (41). Song et al. also explored anti-cancer composite silk nanomaterials for targeted delivery for gene therapies (28). They utilized a salting out technique to fabricate magnetic silk + polyethyleneimine core shell nanoparticles with tunable size (~100-500 nm). They demonstrated enhanced delivery of therapeutic antisense oligodeoxynucleotides by use of magnetofection in MDA-MB-231 breast cancer cells (28). Silk-based nanomaterial DDS continue to be made of primarily *Bombyx mori* fibroin polymers, but recently researchers have also begun investigating other silk fiber biopolymers as well as alternative sources for silk fibroin biopolymers that have additional unique properties for use in biomedical applications.

### *Bombyx mori* sericin

As mentioned previously, sericin proteins from *Bombyx mori* cocoons have traditionally been discarded as a waste product. However, recent work has highlighted how, when purified, sericin proteins are non-cytotoxic, have a high potential for reactive modification, and can facilitate cell-material interaction. A major limitation of sericin proteins is that they are highly water soluble, meaning the majority of nanomaterials made with sericin must be composite materials. Sericins from *Bombyx mori* are not as well characterized as their fibroin counterpart, but it has been shown that they are globular proteins in nature ranging from 20-310 kDa and mainly consist of reactive residues like serine and aspartic acid. This means sericin materials often have increased presence of random coil structures; however, crystallinity can still be induced in the material synthesis process by techniques such as desolvation. Recent studies utilizing sericin-based DDS have focused on applications including nasal delivery (48), pH responsive materials (49), antibacterial activity (50, 51), cell therapy (52), and cancer therapies (53-55) (**Table 1**).

To assemble sericin-based nanoparticles, researchers often have taken a two-step approach. First, taking advantage of the reactivity of sericin, they chemically crosslink or modify the polymer. This is typically followed by a self-assembly or desolvation step. Boonpavanitchakul et

al. conjugated a hydrophobic polymer, PLA, to sericin, forming an amphiphilic material (53). They were then able to self-assemble the PLA-silk sericin polymers into nanomaterials of tunable size (~36-370 nm) depending on the pH and inclusion of additional crosslinkers, all taking place in aqueous conditions. They further demonstrated the potential of this system as a cancer therapy by showing effective loading of doxorubicin, enhanced release under acidic conditions, and effectiveness in *in vitro* liver cancer cell models (53). Perteghella et al. stabilized sericin by crosslinking with crocetin and formed ~225 nm nanoparticles by desolvation in acetone (48). Perteghella and colleagues are working toward optimizing these particles for nose-to-brain delivery and demonstrated cytocompatibility and protection from oxidative stress in Caco-2 epithelial cells (48). Xu et al. took a novel approach and optimized a transgenic silkworm to produce silk that is sericin-rich and has recombinant lactoferrin expressed in the sericin layer for treatment of ulcerative colitis (49). They were then able to synthesize ~125 nm negatively charged sericin-lactoferrin nanospheres by acetone desolvation. The effectiveness of the system was evaluated by oral delivery in an ulcerative colitis mouse model. They demonstrated improved uptake efficiency (attributed to charge interactions) and inhibition of the NF- $\kappa$ B inflammatory pathway associated with acute colitis (49). Overall, the recent progress in sericin DDS highlight the advantages of the increased bioactivity and reactivity of the protein. Researchers have also begun to evaluate the potential of silk from different species for this same purpose.

#### Non-*Bombyx mori* native silk fibers

While most silk-based healthcare materials have traditionally been reverse engineered from *Bombyx mori* silk fibers, most insects in the Lepidopteran order produce silk fibers for a variety of applications (cocoon/web formation, egg coating, etc.). Recent studies have found that some of these fibers expand the design space for silk-based materials by having more reactive residues and different mechanical properties. Recently, silk fibroin from *Antheraea assamensis* (56, 57), *Antheraea pernyi* (58), and sericin from *Antheraea mylitta* (59) have all been used in the development of nanoparticle DDS (**Table 1**).

Asapur et al. characterized the secondary structure of nanoparticles synthesized from *Antheraea assamensis* fibroin by desolvation and radiolysis methods (56). The fibroin from *Antheraea assamensis* is known for its ability to absorb high levels of UV radiation and its impressive tensile strength. Asapur et al. characterized the secondary structure of nanoparticles synthesized from *Antheraea assamensis* fibroin by desolvation and radiolysis methods (56). The fibroin from *Antheraea assamensis* is known for its ability to absorb high levels of UV radiation and its impressive tensile strength (60). Like *Bombyx mori* fibroin, alanine-rich repeating motifs give this biopolymer the potential to form nanomaterials with high levels of  $\beta$  sheet crystallinity (61). Asapur et al. found that the radiolysis method led to the formation of smaller ~180 nm particles compared to ~250 nm particles made with desolvation. Both particle types also had >30% crystalline content, showing potential for controlled release (56). Baruah et al. evaluated the release of doxorubicin from *Antheraea assamensis* fibroin particles made by desolvation and found efficient drug loading, and that the DDS increased the effectiveness relative to free

doxorubicin of the cytotoxic effect on MDA-MB-231 cancer cells (57). . Asapur et al found that the radiolysis method led to the formation of smaller ~180 nm particles compared to ~250 nm particles made with desolvation. Both particle types also had >30% crystalline content, showing potential for controlled release (56). Baruah et al. evaluated the release of doxorubicin from *Antheraea assamensis* fibroin particles made by desolvation and found efficient drug loading, and that the DDS increased the effectiveness relative to free doxorubicin of the cytotoxic effect on MDA-MB-231 cancer cells (57).

Liu et al. took advantage of the abundant reactive sites present in silk fibroin from *Antheraea pernyi* in the creation of their stimuli responsive DDS (58). They prepared particles from cationized *Antheraea pernyi* fibroin for gene delivery to cancer cells by desolvation in DMSO. Using the reactive capabilities of this fibroin, they grafted on an MMP-2 cleavable PEG to the particles surface. This allowed for limiting opsonization without sacrificing transfection when MMP-2 (highly expressed in the tumor microenvironment) cleaves the PEG *in vitro*. They demonstrated decreased protein adhesion and successful transfection to HEK293 cells (58). In addition to leveraging the biodiversity of silk fiber producing species to design novel polymeric nanomaterials for DDS, researchers have also recently been producing recombinant proteins inspired by silk fibers to create targeted DDS.

#### Silk fiber-inspired recombinant polymers

As an alternative to use of purified silk fibroin proteins, researchers have also designed recombinant silk proteins inspired by nature to make polymeric nanomaterials for drug and therapeutic delivery. One approach is to use bacteria, such as *E. coli*, to express silk-like peptides either alone or in combination with other useful protein sequences (62-64). Another approach utilizes whole organism genetic modification to express engineered silk fibroins or other related therapeutic agents (e.g., sericins) (49, 65-71).

Much of the focus of genetic engineering of silk proteins is based on the silk fibroins produced by spiders. This is because, unlike Lepidopteran species, spiders' cannibalistic and territorial tendencies make it so spiders cannot be farmed, meaning their fibers cannot be naturally sourced for biomedical research. Researchers have taken inspiration from the silk of *Nephila clavipes* and *Araneus diadematus* to design recombinant spider proteins. Silk produced from spiders (spidroin proteins) are ~300 kDa and composed of a highly repetitive core, mainly consisting of alanine, glycine, and proline residues, flanked by small, nonrepetitive terminal domains, which are highly conserved across spider species (72). The development, expression, and purification of spider-inspired fibroin proteins (spidroin proteins) has been recently reviewed (12, 73). For the purposes of this review, we focus on the nanoparticle fabrication techniques recently used in the progress toward targeted DDS, and recent publications are summarized in **Table 1**.

The Scheibel group designed nanoparticle systems based on *Araneus diadematus* with the goal of directing corona formation and stimuli responsive release (74, 75). They recombinantly produced polymers with either a net negative or net positive charge and used the salting out

technique to form nanoparticles. They then performed *ex vivo* analysis of corona formation in whole blood (74). It was observed that the negatively charged nanospheres primarily attracted complement proteins and immunoglobulins, while positively charged particles primarily had fibrinogen-based proteins adsorbed on their surface (74). In a separate study, researchers utilized a polyanionic form of the silk from the aforementioned study and covalently attached a cytostatic drug to the particle surface and explored the response to pH and redox state (75). Ellman's solution (a model to simulate sulfhydryl group containing drugs) was bound to cystine residues in the spider fibroin-inspired silk particle, which was then further modified by including a hydrazone linker. This system led to enhanced drug release under acidic conditions and oxidative stress in HeLa cultures (75). Researchers have also explored recombinantly producing proteins and peptides inspired by the spidroin proteins of other spider species (76).

The Dam-Kozłowska group has been building toward a cancer therapeutic DDS based on a recombinant silk fiber inspired by *Nephila clavipes* (77-79). They were able to produce a polymer based on the MaSp1 sequence from *Nephila clavipes* and include a Her2 binding peptide. Particles were produced by salting out and loaded with doxorubicin. They demonstrated enhanced binding to Her2-overexpressing SKOV3 cells and showed the particles themselves were noncytotoxic and could deliver doxorubicin to kill cancer cells (77). They recently tested this system *in vivo* and demonstrated safety (79) and targeted delivery in breast cancer models (78). The development of DDS based on silk nanomaterials continues to grow and researchers are moving toward potential for clinical translation.

## Future Perspectives and Conclusion

The wide range of material properties available from the reconstitution of silk fibers makes them an interesting class of materials for future translational research. Specifically, silk fibroins from *Bombyx mori* are able to generate a wide array of drug delivery systems (DDS) given the range of fabrication techniques, modification methods, and utility in composite materials. Furthermore, spider silk-inspired and sericin biopolymers represent additional classes of materials for DDS. Each class of materials offers its own unique features, such as biodegradation, controllable immunogenicity, and favorable mechanical properties.

While many systems have been proposed, grand challenges still exist in the application of these materials to clinical settings. As with any natural material or recombinantly produced protein, ensuring good manufacturing practices as well as methods to remove contaminating molecules or organisms, such as endotoxins or mycotoxins, is critical. Sourcing these natural materials can also be a challenge, as *Bombyx mori* cultivation and farming is subject to our changing climate and regional differences in farming practices (80, 81), which can lead to variability in cocoons and subsequent silk properties. Recent advancements in genetic engineering technologies for the *Bombyx mori* silkworm suggest that improvements or modifications to protein structures within these systems is possible (65, 67-69, 82), thus providing an avenue for addressing current challenges in protein structure highlighted throughout this review. However, any change is not

without added complication or risk, as modification to silk fibroin protein sequences can pose new challenges in protein expression, spinning, or purification. Additionally, chemical modifications to existing natural materials can also alter chemistries for improvements in affinity binding and drug loading (13, 83). Continued efforts to further open the design space to include silk fibers or silk fiber-based proteins from other species as well as recombinantly produced polymers and peptides is another strategy for overcoming current challenges. These efforts demonstrate the enormous future potential for this class of materials and their scale-up, use in advanced manufacturing, generation of novel polymer solutions, and development of treatments for a myriad of diseases. While this review was limited to nanomaterial-based DDS, we expect that the use of novel silk proteins for the formation of materials such as scaffolds, films, foams, and hydrogels is an area of interest for local DDS, regenerative medicine, and tissue engineering. Similarly, clinical trials using materials from or synthesized to replicate components silk fibers are on-going, with a large focus on inert filler materials for treatment of conditions like vocal cord paralysis (84). These advances toward clinical application are positive first steps for the continued investigation and development of all-natural silk-inspired nanomaterials for drug delivery systems.

**Table 1:** Summary of current advances in silk and silk fiber-inspired nanomaterials for drug and gene delivery

| Polymer Source                | Fabrication Strategy  | Particle Size | Application                                                           | <i>In vitro</i> and/or <i>in vivo</i> models                                                                                                                                                                  | Refs. |
|-------------------------------|-----------------------|---------------|-----------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|
| <b><i>B. mori</i> fibroin</b> | Chemical crosslinking | 50-100 nm     | Molecular imprinting                                                  | <i>In vitro</i> : 3T3 cytotoxicity                                                                                                                                                                            | (39)  |
|                               | Nanoprecipitation     | 200-220 nm    | pH responsive Silk-ZIF-8 core-shell nanospheres, Doxorubicin delivery | <i>In vitro</i> : MCF-7 cytotoxicity, uptake and localization<br><i>In vivo</i> : subcutaneous injection in BALB/c nude mice safety evaluation<br>MCF-7 tumor bearing mice-therapeutic anti-tumor effect      | (20)  |
|                               | Desolvation           | 175-225 nm    | NAC nasal delivery                                                    | <i>In vitro</i> : TEER assays and tight junction analysis in human nasal RPMI 2650<br><i>In vivo</i> : Sprague Dawley IVIS study                                                                              | (35)  |
|                               | Desolvation           | 110 nm        | Celecoxib and curcumin delivery for osteoarthritis                    | <i>In vitro</i> : isolated articular chondrocyte inflammation model                                                                                                                                           | (85)  |
|                               | Desolvation           | 200-300 nm    | cRGD functionalized silk for targeted delivery of patchouli alcohol   | <i>In vitro</i> : anti-inflammation assays in RAW 264.7 macrophages, Intestinal barrier protection evaluation in Caco-2 cells<br><i>In vivo</i> : biodistribution and therapeutic outcomes evaluation in mice | (42)  |

|  |                                                                                                           |              |                                                                                                                   |                                                                                                                          |      |
|--|-----------------------------------------------------------------------------------------------------------|--------------|-------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|------|
|  | Spray drying                                                                                              | ~165-260 nm  | Rosmarinic acid delivery to cancer cells                                                                          | <i>In vitro</i> : cellular uptake, and cytotoxicity assays                                                               | (25) |
|  | Desolvation                                                                                               | 300-400 nm   | NO delivery                                                                                                       | <i>In vitro</i> : viability assays with 3T3 cells, antibacterial effect on viability with <i>E. coli</i> and <i>MRSA</i> | (86) |
|  | Desolvation                                                                                               | 100-180 nm   | Silk particles as adjuvants in subunit multi epitope vaccine for UTI                                              | <i>In vitro</i> : cytotoxicity in L929 cells<br><i>In vivo</i> : immunization assay in BALB/c mice                       | (27) |
|  | Desolvation                                                                                               | ~160-190 nm  | Targeted delivery of ferulic acid by neutrophil coating of silk particles for pancreatitis                        | <i>In vivo</i> : IV injection in male Wistar rats. Biodistribution and therapeutic effect                                | (40) |
|  | *ionic gelation, green synthesis<br><br>Chemical crosslinking<br><br>*processing steps not involving silk | ~8 nm, ~1 µm | Chitosan-gold nanoparticles coated in functionalized silk fibroin for targeted delivery of doxorubicin            | <i>In vitro</i> : HeLa cell viability and live cell imaging                                                              | (41) |
|  | Emulsion polymerization                                                                                   | 38-220 nm    | PEGylated fibroin nanoparticles for 5-FU delivery in treatment of colorectal cancer                               | <i>In vitro</i> : HT-29 cytotoxicity assays                                                                              | (87) |
|  | Semi-batch processing using micromixing and microfluidics-desolvation                                     | 109-149 nm   | Volumetric scale up of silk particles to enhance the potential for translation                                    | ---                                                                                                                      | (33) |
|  | Desolvation and pH induced self-assembly                                                                  | 106-165 nm   | Respiratory delivery of rifampicin for treatment of mycobacterial disease                                         | <i>In vitro</i> : inflammatory response of infected RAW 264.7 macrophages                                                | (37) |
|  | Desolvation                                                                                               | 186 nm       | Delivery of tamoxifen citrate for treatment in breast cancer                                                      | <i>In vitro</i> : cytotoxicity and uptake in MCF-10A (noncancerous), MCF-7 and MDA-MB-231 (cancerous) lines              | (88) |
|  | Self-assembly                                                                                             | 120-170 nm   | Delivery of gene therapies for treatments of lung cancer by chemically modified, cationized silk fibroin carriers | <i>In vitro</i> : transfection and viability analysis in A549 and WI-38 cells                                            | (89) |
|  | Desolvation                                                                                               | 69 nm        | Delivery of antioxidant and imaging agents (theragnostic)                                                         | <i>In vitro</i> : cytotoxicity in L132 and A549 cells                                                                    | (47) |

|  |                                                                                     |                  |                                                                                                                                                      |                                                                                                                                                                                                                    |      |
|--|-------------------------------------------------------------------------------------|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
|  | Desolvation and chemical crosslinking                                               | 300-500 nm       | Delivery of paclitaxel for colon cancer treatment                                                                                                    | <i>In vitro</i> : cytotoxicity and uptake in Caco-2 and MCF-7 cells.                                                                                                                                               | (43) |
|  | Desolvation                                                                         | 92-200 nm        | Composite silk fibroin/alginate nanoparticles in PNIPAM hydrogel for pH sensitive delivery of vancomycin for treatment of infection in chronic burns | <i>In vitro</i> : biocompatibility, cell migration analysis with L929 cells<br><i>In vivo</i> : infected burn model in male Wistar albino rats                                                                     | (21) |
|  | Salting out                                                                         | 107-436 nm       | Magnetic silk+polyethyleneimine core shell for targeted delivery of gene therapies in treatment of breast cancer                                     | <i>In vitro</i> : cytotoxicity and uptake analysis in MDA-MB-231 or HDF cells                                                                                                                                      | (28) |
|  | *thin film hydration<br><br>Desolvation<br><br>*processing steps not involving silk | 136-191 nm       | Long-term delivery of cancer therapies (doxorubicin)                                                                                                 | <i>In vitro</i> : cytotoxicity in L929, MDA-MB-231 and MCF-7 cells                                                                                                                                                 | (90) |
|  | Desolvation                                                                         | 36-48 nm         | Transdermal deliveries of therapies                                                                                                                  | <i>In vivo</i> : transdermal distribution study in male ICR mice                                                                                                                                                   | (36) |
|  | Microfluidic assisted desolvation                                                   | 129-232 nm       | Targeted delivery by G3 functionalized particles of cancer therapy ASC-J9                                                                            | <i>In vitro</i> : cytotoxicity, uptake, and tumor spheroid penetration in HCT-116 and DF cells                                                                                                                     | (32) |
|  | Co-flow microfluidic device assisted desolvation                                    | ~6 $\mu$ m       | Doxorubicin delivery to tumor microenvironment                                                                                                       | <i>In vitro</i> : cytotoxicity, inflammation response, uptake in KELLY and THP-1 cells                                                                                                                             | (30) |
|  | Water/oil emulsion                                                                  | 20-140 $\mu$ m   | Injectable microspheres analysis for future delivery in treatment of osteoarthritis                                                                  | <i>In vitro</i> : cytocompatibility analysis with rat bone MSCs<br><br><i>In vivo</i> : subcutaneous injections in Sprague Dawley rats for biocompatibility analysis, ACL transection model in Sprague Dawley rats | (91) |
|  | Concentration followed by incubation to induce self-assembly                        | 100 nm-1 $\mu$ m | Delivery of cancer therapies (doxorubicin)                                                                                                           | <i>In vitro</i> : uptake, retention, cytotoxicity analysis in HUVEC and MCF-7 cells. Tumor spheroid penetration (MCF-7)                                                                                            | (34) |
|  | Desolvation                                                                         | 179 nm           | Delivery of biotherapeutics to the retina                                                                                                            | <i>In vitro</i> : cytotoxicity, uptake, retention analysis in ARPE-19 cells                                                                                                                                        | (38) |

|                                        |                                                |            |                                                                                                                           |                                                                                                                                                                                                                           |      |
|----------------------------------------|------------------------------------------------|------------|---------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
|                                        |                                                |            |                                                                                                                           | <i>In vivo</i> : biodistribution and safety of intravitreal injection in white New Zealand rabbits                                                                                                                        |      |
|                                        | Desolvation and freezing induced self-assembly | 330-379 nm | Delivery of gene therapies                                                                                                | <i>In vitro</i> : cytotoxicity, uptake, immunostimulation in RAW 264.7                                                                                                                                                    | (92) |
|                                        | Desolvation                                    | 53-73 nm   | MnO <sub>2</sub> capped silk fibroin particles for photodynamic therapy for cancer                                        | <i>In vitro</i> : viability in L929 and HUVEC cells. Cytotoxicity and uptake in 4T1 cells.<br><i>In vivo</i> : evaluation of biodistribution, pharmacokinetics, and antitumor effects in a 3T1 tumor model in BALB/c mice | (45) |
|                                        | Desolvation                                    | 120 nm     | Indocyanine green loaded silk particles for photo-thermal treatment of glioma                                             | <i>In vitro</i> : cytotoxicity and uptake in RAW 264.7 and C6 cells. Photo-thermal effect with C6 cells.<br><i>In vivo</i> : biodistribution, pharmacokinetics, and antitumor effects in C6 tumor model in BALB/c mice    | (46) |
| <b><i>B. mori</i> sericin</b>          | Self-assembly in water                         | 35-370 nm  | Sericin-PLA are chemically conjugated to form an amphiphilic material for doxorubicin delivery                            | <i>In vitro</i> : cytotoxicity and uptake in HepG2 cells                                                                                                                                                                  | (53) |
|                                        | Self-assembly in DMSO with Pluronic F-127      | 137-201 nm | Slow release of antioxidant polyphenols for support of regeneration by MSCs                                               | <i>In vitro</i> : cytocompatibility and proliferation assays in human adipose derived MSCs                                                                                                                                | (52) |
|                                        | Chemical crosslinking followed by desolvation  | 225-248 nm | Evaluating crocetin as novel crosslinker for bioactive sericin particles for nasal delivery and limiting oxidative stress | <i>In vitro</i> : metabolic activity assay in Caco-2 cells                                                                                                                                                                | (48) |
|                                        | Nanoprecipitation                              | 100-300 nm | Doxorubicin delivery in treatment of breast cancer                                                                        | <i>In vitro</i> : cytotoxicity, cytoskeletal changes, and comet assays in MCF-7 cells                                                                                                                                     | (54) |
|                                        | Desolvation                                    | 123-147 nm | pH responsive, targeted delivery of lactoferrin for treatment of ulcerative colitis                                       | <i>In vitro</i> : cytotoxicity, cellular uptake, and anti-inflammatory activity in RAW 264.7 cells<br><i>In vivo</i> : ulcerative colitis model in BALB/c mice                                                            | (49) |
| <b>Non-<i>B. mori</i> native silks</b> | Desolvation and radiolysis                     | 180-250 nm | Characterization of secondary structure of <i>Antheraea assamensis</i> fibroin nanoparticles                              | ---                                                                                                                                                                                                                       | (56) |

|                   |                   |            |                                                                                                                |                                                                                                                                                                                         |      |
|-------------------|-------------------|------------|----------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
|                   |                   |            | for applications in controlled release                                                                         |                                                                                                                                                                                         |      |
|                   | Desolvation       | 185 nm     | Release of doxorubicin from <i>Antheraea assamensis</i> fibroin nanoparticles for cancer treatment             | <i>In vitro</i> : biocompatibility in L929 cells. Cytotoxicity in MDA-MB-231 cells                                                                                                      | (57) |
|                   | Desolvation       | 400-800 nm | Stimuli responsive, PEG- <i>Antheraea pernyi</i> silk particles for gene therapy in cancer                     | <i>In vitro</i> : transfection and cytotoxicity assays in HT1080 and HEK293 cells                                                                                                       | (58) |
|                   | Self-assembly     | 109-155 nm | Chitosan and <i>Antheraea mylitta</i> silk-coated silver nanoparticles for transdermal cancer therapy delivery | <i>In vitro</i> : cytotoxicity, comet, morphology assays in A431 and HaCaT cells<br><i>In vivo</i> : immune response in BALB/c mice                                                     | (59) |
| Recombinant silks | Salting out       | ~400 nm    | Targeted delivery of doxorubicin for cancer in particle inspired by <i>Nephila clavipes</i> spider             | <i>In vivo</i> : biodistribution and safety in BALB/cAnNCrI mice                                                                                                                        | (79) |
|                   | Salting out       | ~400 nm    | Targeted delivery of doxorubicin for cancer in particle inspired by <i>Nephila clavipes</i> spider             | <i>In vitro</i> : cytotoxicity, and uptake in D2F2E2/LUC and D2F2/LUC cells<br><i>In vivo</i> -models for orthotopic and metastatic breast cancer in BALB/cAnNCrI mice                  | (78) |
|                   | Salting out       | ~1 $\mu$ m | Stimuli responsive <i>Araneus diadematus</i> inspired particle for cancer therapy delivery                     | <i>In vitro</i> : cytotoxicity and uptake in HeLa cells                                                                                                                                 | (75) |
|                   | Nanoprecipitation | 184 nm     | Stimuli responsive <i>Nephila clavipes</i> inspired particles for antibiotic delivery                          | <i>In vitro</i> : infection responsive activity in <i>Staphylococcus aureus</i> and <i>Staphylococcus epidermidis</i><br><i>In vivo</i> : septic arthritis model in Sprague Dawley rats | (93) |
|                   | Salting out       | ~1 $\mu$ m | <i>Araneus diadematus</i> inspired particles for directing corona formation, applications in systemic delivery | <i>Ex vivo</i> : incubation in human whole blood for corona analysis                                                                                                                    | (74) |

## Author Contributions

**MOP**: Writing-Original Draft, Review & Editing, Visualization, Conceptualization **LEE**: Visualization, Writing-Review & Editing **NAD**: Visualization, Writing-Review & Editing **JA**: Writing-Review & Editing **ASC**: Writing-Review & Editing **IPK**: Writing-Review & Editing **WLS**: Writing-

Review & Editing, Conceptualization, Supervision. All authors have read and agreed to the final version of the manuscript.

## Funding

All authors would like to acknowledge support from the Department of Defense Congressionally Directed Medical Research Fund (W81XWH2110199). LEE and ASC acknowledge support from the REU in Chemical Engineering REU Site at the University of Florida (NSF EEC-1852111). NAD was supported by a grant from the National Institutes of Health (NIH T35HL007489). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. MOP acknowledges support from the National Science Foundation Graduate Research Fellowship (DGE-1842473). Any opinions, findings, and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the National Science Foundation or another funding agency. IPK would like to acknowledge support from the UF Student Science Training Program (SSTP) and her summer research experience.

## Conflict of Interest

The authors declare no conflict of interest.

## Acknowledgments

The Stoppel Lab would like to acknowledge the University of Florida (UF) Chemical Engineering Research Experience for Undergraduates program, the UF Herbert Wertheim College of Engineering Summer Undergraduate Research at Florida (SURF) Program, the UF Student Science Training Program, and the UF College of Medicine Medical Student Research Program for supporting development of trainees in the laboratory during Summer 2022. Figure 1 was created with a license from BioRender.com.

## References

1. Jain KK. An Overview of Drug Delivery Systems. *Methods Mol Biol.* 2020;2059:1-54. Epub 2019/08/23. doi: 10.1007/978-1-4939-9798-5\_1. PubMed PMID: 31435914.
2. Hrkach J, Langer R. From micro to nano: evolution and impact of drug delivery in treating disease. *Drug Deliv Transl Res.* 2020;10(3):567-70. Epub 2020/05/10. doi: 10.1007/s13346-020-00769-6. PubMed PMID: 32385828; PMCID: PMC7209970.
3. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. *Nat Biotechnol.* 2015;33(9):941-51. Epub 2015/09/09. doi: 10.1038/nbt.3330. PubMed PMID: 26348965; PMCID: PMC4978509.
4. Brannon ER, Guevara MV, Pacifici NJ, Lee JK, Lewis JS, Eniola-Adefeso O. Polymeric particle-based therapies for acute inflammatory diseases. *Nat Rev Mater.* 2022;7(10):796-813. Epub 2022/07/26. doi: 10.1038/s41578-022-00458-5. PubMed PMID: 35874960; PMCID: PMC9295115.

5. Chen L, Hong W, Ren W, Xu T, Qian Z, He Z. Recent progress in targeted delivery vectors based on biomimetic nanoparticles. *Signal Transduct Target Ther.* 2021;6(1):225. Epub 2021/06/09. doi: 10.1038/s41392-021-00631-2. PubMed PMID: 34099630; PMCID: PMC8182741.
6. George A, Shah PA, Shrivastav PS. Natural biodegradable polymers based nano-formulations for drug delivery: A review. *Int J Pharm.* 2019;561:244-64. Epub 2019/03/10. doi: 10.1016/j.ijpharm.2019.03.011. PubMed PMID: 30851391.
7. Jameson JF, Pacheco MO, Butler JE, Stoppel WL. Estimating Kinetic Rate Parameters for Enzymatic Degradation of Lyophilized Silk Fibroin Sponges. *Front Bioeng Biotechnol.* 2021;9(537):664306. Epub 2021/07/24. doi: 10.3389/fbioe.2021.664306. PubMed PMID: 34295878; PMCID: PMC8290342.
8. Guo C, Li C, Kaplan DL. Enzymatic Degradation of Bombyx mori Silk Materials: A Review. *Biomacromolecules.* 2020;21(5):1678-86. Epub 2020/02/11. doi: 10.1021/acs.biomac.0c00090. PubMed PMID: 32040910; PMCID: PMC7645160.
9. Pham DT, Tiayaboonchai W. Fibroin nanoparticles: a promising drug delivery system. *Drug Deliv.* 2020;27(1):431-48. Epub 2020/03/12. doi: 10.1080/10717544.2020.1736208. PubMed PMID: 32157919; PMCID: PMC7144220.
10. Wongpinyochit T, Vassileiou AD, Gupta S, Mushrif SH, Johnston BF, Seib FP. Unraveling the Impact of High-Order Silk Structures on Molecular Drug Binding and Release Behaviors. *J Phys Chem Lett.* 2019;10(15):4278-84. Epub 2019/07/19. doi: 10.1021/acs.jpclett.9b01591. PubMed PMID: 31318218.
11. Asakura T, Okushita K, Williamson MP. Analysis of the Structure of Bombyx mori Silk Fibroin by NMR. *Macromolecules.* 2015;48(8):2345-57. doi: 10.1021/acs.macromol.5b00160. PubMed PMID: WOS:000353864800001.
12. Bittencourt DMC, Oliveira P, Michalczechen-Lacerda VA, Rosinha GMS, Jones JA, Rech EL. Bioengineering of spider silks for the production of biomedical materials. *Front Bioeng Biotechnol.* 2022;10:958486. Epub 2022/08/27. doi: 10.3389/fbioe.2022.958486. PubMed PMID: 36017345; PMCID: PMC9397580.
13. Heichel DL, Burke KA. Enhancing the Carboxylation Efficiency of Silk Fibroin through the Disruption of Noncovalent Interactions. *Bioconj Chem.* 2020;31(5):1307-12. Epub 2020/05/08. doi: 10.1021/acs.bioconjchem.0c00168. PubMed PMID: 32378886.
14. Murphy AR, St John P, Kaplan DL. Modification of silk fibroin using diazonium coupling chemistry and the effects on hMSC proliferation and differentiation. *Biomaterials.* 2008;29(19):2829-38. Epub 2008/04/18. doi: 10.1016/j.biomaterials.2008.03.039. PubMed PMID: 18417206; PMCID: PMC2698958.
15. Murphy AR, Kaplan DL. Biomedical applications of chemically-modified silk fibroin. *J Mater Chem.* 2009;19(36):6443-50. Epub 2010/02/18. doi: 10.1039/b905802h. PubMed PMID: 20161439; PMCID: PMC2790051.
16. Ode Boni BO, Bakadia BM, Osi AR, Shi Z, Chen H, Gauthier M, Yang G. Immune Response to Silk Sericin-Fibroin Composites: Potential Immunogenic Elements and Alternatives for Immunomodulation.

Macromol Biosci. 2022;22(1):e2100292. Epub 2021/10/21. doi: 10.1002/mabi.202100292. PubMed PMID: 34669251.

17. Rockwood DN, Preda RC, Yucel T, Wang X, Lovett ML, Kaplan DL. Materials fabrication from Bombyx mori silk fibroin. Nat Protoc. 2011;6(10):1612-31. Epub 2011/10/01. doi: 10.1038/nprot.2011.379. PubMed PMID: 21959241; PMCID: PMC3808976.

18. Zhou CZ, Confalonieri F, Jacquet M, Perasso R, Li ZG, Janin J. Silk fibroin: structural implications of a remarkable amino acid sequence. Proteins. 2001;44(2):119-22. Epub 2001/06/08. doi: 10.1002/prot.1078. PubMed PMID: 11391774.

19. Hu X, Shmelev K, Sun L, Gil ES, Park SH, Cebe P, Kaplan DL. Regulation of silk material structure by temperature-controlled water vapor annealing. Biomacromolecules. 2011;12(5):1686-96. Epub 2011/03/24. doi: 10.1021/bm200062a. PubMed PMID: 21425769; PMCID: PMC3090511.

20. Chen Y, Wu H, Yang T, Zhou G, Chen Y, Wang J, Mao C, Yang M. Biomimetic Nucleation of Metal-Organic Frameworks on Silk Fibroin Nanoparticles for Designing Core-Shell-Structured pH-Responsive Anticancer Drug Carriers. ACS Appl Mater Interfaces. 2021;13(40):47371-81. Epub 2021/09/29. doi: 10.1021/acsami.1c13405. PubMed PMID: 34582680.

21. Rezaei F, Damoogh S, Reis RL, Kundu SC, Mottaghitlab F, Farokhi M. Dual drug delivery system based on pH-sensitive silk fibroin/alginate nanoparticles entrapped in PNIPAM hydrogel for treating severe infected burn wound. Biofabrication. 2020;13(1):015005. Epub 2020/10/21. doi: 10.1088/1758-5090/abbb82. PubMed PMID: 33078712.

22. Seib FP, Jones GT, Rnjak-Kovacina J, Lin Y, Kaplan DL. pH-dependent anticancer drug release from silk nanoparticles. Adv Healthc Mater. 2013;2(12):1606-11. Epub 2013/04/30. doi: 10.1002/adhm.201300034. PubMed PMID: 23625825; PMCID: PMC3808531.

23. Hong S, Choi DW, Kim HN, Park CG, Lee W, Park HH. Protein-Based Nanoparticles as Drug Delivery Systems. Pharmaceutics. 2020;12(7). Epub 2020/07/03. doi: 10.3390/pharmaceutics12070604. PubMed PMID: 32610448; PMCID: PMC7407889.

24. Wenk E, Murphy AR, Kaplan DL, Meinel L, Merkle HP, Uebersax L. The use of sulfonated silk fibroin derivatives to control binding, delivery and potency of FGF-2 in tissue regeneration. Biomaterials. 2010;31(6):1403-13. Epub 2009/11/28. doi: 10.1016/j.biomaterials.2009.11.006. PubMed PMID: 19942287.

25. Fuster MG, Carissimi G, Montalban MG, Villora G. Antitumor Activity of Rosmarinic Acid-Loaded Silk Fibroin Nanoparticles on HeLa and MCF-7 Cells. Polymers (Basel). 2021;13(18):3169. Epub 2021/09/29. doi: 10.3390/polym13183169. PubMed PMID: 34578069; PMCID: PMC8467615.

26. Zahedi P, Besheli NH, Farokhi M, Mottaghitlab F, Sohrabi A, Ghorbanian SA. Silk Fibroin Nanoparticles Functionalized with Fibronectin for Release of Vascular Endothelial Growth Factor to Enhance Angiogenesis. Journal of Natural Fibers. 2021;1-12. doi: 10.1080/15440478.2021.1982814. PubMed PMID: WOS:000704275100001.

27. Hasanzadeh S, Farokhi M, Habibi M, Shokrgozar MA, Ahangari Cohan R, Rezaei F, Asadi Karam MR, Bouzari S. Silk Fibroin Nanoadjuvant as a Promising Vaccine Carrier to Deliver the FimH-lutA Antigen

for Urinary Tract Infection. *ACS Biomater Sci Eng.* 2020;6(8):4573-82. Epub 2021/01/19. doi: 10.1021/acsbiomaterials.0c00736. PubMed PMID: 33455198.

28. Song W, Gregory DA, Al-Janabi H, Muthana M, Cai Z, Zhao X. Magnetic-silk/polyethyleneimine core-shell nanoparticles for targeted gene delivery into human breast cancer cells. *Int J Pharm.* 2019;555:322-36. Epub 2018/11/19. doi: 10.1016/j.ijpharm.2018.11.030. PubMed PMID: 30448314.

29. Shimanovich U, Ruggeri FS, De Genst E, Adamcik J, Barros TP, Porter D, Müller T, Mezzenga R, Dobson CM, Vollrath F, Holland C, Knowles TPJ. Silk micrococoon for protein stabilisation and molecular encapsulation. *Nature Communications.* 2017;8(1):15902. doi: 10.1038/ncomms15902.

30. Vargas Montoya N, Peterson R, Ornell KJ, Albrecht DR, Coburn JM. Silk Particle Production Based on Silk/PVA Phase Separation Using a Microfabricated Co-flow Device. *Molecules.* 2020;25(4):890. PubMed PMID: doi:10.3390/molecules25040890.

31. Matthew SAL, Totten JD, Phuagkhaopong S, Egan G, Witte K, Perrie Y, Seib FP. Silk Nanoparticle Manufacture in Semi-Batch Format. *ACS Biomater Sci Eng.* 2020;6(12):6748-59. Epub 2020/12/16. doi: 10.1021/acsbiomaterials.0c01028. PubMed PMID: 33320640.

32. Tomeh MA, Hadianamrei R, Xu D, Brown S, Zhao X. Peptide-functionalised magnetic silk nanoparticles produced by a swirl mixer for enhanced anticancer activity of ASC-J9. *Colloids and surfaces B, Biointerfaces.* 2022;216:112549. Epub 2022/06/01. doi: 10.1016/j.colsurfb.2022.112549. PubMed PMID: 35636321.

33. Matthew SAL, Rezwan R, Perrie Y, Seib FP. Volumetric Scalability of Microfluidic and Semi-Batch Silk Nanoprecipitation Methods. *Molecules.* 2022;27(7):2368. Epub 2022/04/13. doi: 10.3390/molecules27072368. PubMed PMID: 35408763; PMCID: PMC9000471.

34. Xiao L, Ding Z, Zhang X, Wang X, Lu Q, Kaplan DL. Silk Nanocarrier Size Optimization for Enhanced Tumor Cell Penetration and Cytotoxicity In Vitro. *ACS Biomater Sci Eng.* 2022;8(1):140-50. Epub 2021/12/09. doi: 10.1021/acsbiomaterials.1c01122. PubMed PMID: 34878245.

35. Chung TW, Wu TY, Siah ZY, Liu DZ. Antioxidative NAC-Loaded Silk Nanoparticles with Opening Mucosal Tight Junctions for Nasal Drug Delivery: An In Vitro and In Vivo Study. *Pharmaceutics.* 2022;14(6):1288. Epub 2022/06/25. doi: 10.3390/pharmaceutics14061288. PubMed PMID: 35745861; PMCID: PMC9229699.

36. Takeuchi I, Shimamura Y, Kakami Y, Kameda T, Hattori K, Miura S, Shirai H, Okumura M, Inagi T, Terada H, Makino K. Transdermal delivery of 40-nm silk fibroin nanoparticles. *Colloids and surfaces B, Biointerfaces.* 2019;175:564-8. Epub 2018/12/24. doi: 10.1016/j.colsurfb.2018.12.012. PubMed PMID: 30579057.

37. Mitra K, Chadha A, Muthuvijayan V, Doble M. Self-Assembled Inhalable Immunomodulatory Silk Fibroin Nanocarriers for Enhanced Drug Loading and Intracellular Antibacterial Activity. *ACS Biomater Sci Eng.* 2022;8(2):708-21. Epub 2022/01/22. doi: 10.1021/acsbiomaterials.1c01357. PubMed PMID: 35060708.

38. Yang P, Dong Y, Huang D, Zhu C, Liu H, Pan X, Wu C. Silk fibroin nanoparticles for enhanced bio-macromolecule delivery to the retina. *Pharm Dev Technol.* 2019;24(5):575-83. Epub 2018/11/21. doi: 10.1080/10837450.2018.1545236. PubMed PMID: 30457420.
39. Bossi AM, Bucciarelli A, Maniglio D. Molecularly Imprinted Silk Fibroin Nanoparticles. *ACS Appl Mater Interfaces.* 2021;13(27):31431-9. Epub 2021/07/01. doi: 10.1021/acsami.1c05405. PubMed PMID: 34190536; PMCID: PMC8289228.
40. Hassanzadeh P, Arbabi E, Rostami F. Coating of ferulic acid-loaded silk fibroin nanoparticles with neutrophil membranes: A promising strategy against the acute pancreatitis. *Life Sci.* 2021;270:119128. Epub 2021/01/29. doi: 10.1016/j.lfs.2021.119128. PubMed PMID: 33508299.
41. Horo H, Bhattacharyya S, Mandal B, Kundu LM. Synthesis of functionalized silk-coated chitosan-gold nanoparticles and microparticles for target-directed delivery of antitumor agents. *Carbohydr Polym.* 2021;258:117659. Epub 2021/02/18. doi: 10.1016/j.carbpol.2021.117659. PubMed PMID: 33593545.
42. Du Y, Shi J, Duan R, Tsim KWK, Shen L, Zhang N, Wang B. cRGD peptide incorporated with patchouli alcohol loaded silk fibroin nanoparticles for enhanced targeting of inflammatory sites in colitis. *Biomater Adv.* 2022;140:213069. Epub 2022/08/13. doi: 10.1016/j.bioadv.2022.213069. PubMed PMID: 35961188.
43. Pham DT, Saelim N, Tiyaaboonchai W. Paclitaxel loaded EDC-crosslinked fibroin nanoparticles: a potential approach for colon cancer treatment. *Drug Deliv Transl Res.* 2020;10(2):413-24. Epub 2019/11/09. doi: 10.1007/s13346-019-00682-7. PubMed PMID: 31701488.
44. Totten JD, Wongpinyochit T, Carrola J, Duarte IF, Seib FP. PEGylation-Dependent Metabolic Rewiring of Macrophages with Silk Fibroin Nanoparticles. *ACS Appl Mater Interfaces.* 2019;11(16):14515-25. Epub 2019/04/13. doi: 10.1021/acsami.8b18716. PubMed PMID: 30977355.
45. Zhang L, Yang R, Yu H, Xu Z, Kang Y, Cui H, Xue P. MnO<sub>2</sub>-capped silk fibroin (SF) nanoparticles with chlorin e6 (Ce6) encapsulation for augmented photo-driven therapy by modulating the tumor microenvironment. *J Mater Chem B.* 2021;9(17):3677-88. Epub 2021/05/06. doi: 10.1039/d1tb00296a. PubMed PMID: 33949613.
46. ZhuGe DL, Wang LF, Chen R, Li XZ, Huang ZW, Yao Q, Chen B, Zhao YZ, Xu HL, Yuan JD. Cross-linked nanoparticles of silk fibroin with proanthocyanidins as a promising vehicle of indocyanine green for photo-thermal therapy of glioma. *Artif Cells Nanomed Biotechnol.* 2019;47(1):4293-304. Epub 2019/12/08. doi: 10.1080/21691401.2019.1699819. PubMed PMID: 31810396.
47. Passi M, Kumar V, Packirisamy G. Theranostic nanozyme: Silk fibroin based multifunctional nanocomposites to combat oxidative stress. *Mater Sci Eng C Mater Biol Appl.* 2020;107:110255. Epub 2019/11/26. doi: 10.1016/j.msec.2019.110255. PubMed PMID: 31761203.
48. Perteghella S, Rassu G, Gavini E, Obinu A, Bari E, Mandracchia D, Bonferoni MC, Giunchedi P, Torre ML. Crocetin as New Cross-Linker for Bioactive Sericin Nanoparticles. *Pharmaceutics.* 2021;13(5):680. Epub 2021/06/03. doi: 10.3390/pharmaceutics13050680. PubMed PMID: 34065101; PMCID: PMC8150760.

49. Xu S, Yang Q, Wang R, Tian C, Ji Y, Tan H, Zhao P, Kaplan DL, Wang F, Xia Q. Genetically engineered pH-responsive silk sericin nanospheres with efficient therapeutic effect on ulcerative colitis. *Acta Biomater.* 2022;144:81-95. Epub 2022/03/16. doi: 10.1016/j.actbio.2022.03.012. PubMed PMID: 35288310.
50. Baker A, Syed A, Alyousef AA, Arshad M, Alqasim A, Khalid M, Khan MS. Sericin-functionalized GNPs potentiate the synergistic effect of levofloxacin and balofloxacin against MDR bacteria. *Microb Pathog.* 2020;148:104467. Epub 2020/09/03. doi: 10.1016/j.micpath.2020.104467. PubMed PMID: 32877723.
51. Al Masud MA, Shaikh H, Alam MS, Karim MM, Momin MA, Islam MA, Khan GMA. Green synthesis of silk sericin-embedded silver nanoparticles and their antibacterial application against multidrug-resistant pathogens. *J Genet Eng Biotechnol.* 2021;19(1):74. Epub 2021/05/18. doi: 10.1186/s43141-021-00176-5. PubMed PMID: 33999298; PMCID: PMC8128943.
52. Orlandi G, Bari E, Catenacci L, Sorrenti M, Segale L, Farago S, Sorlini M, Arciola CR, Torre ML, Perteghella S. Polyphenols-Loaded Sericin Self-Assembling Nanoparticles: A Slow-Release for Regeneration by Tissue-Resident Mesenchymal Stem/Stromal Cells. *Pharmaceutics.* 2020;12(4):381. Epub 2020/04/25. doi: 10.3390/pharmaceutics12040381. PubMed PMID: 32326171; PMCID: PMC7238282.
53. Boonpavanitchakul K, Bast LK, Bruns N, Magaraphan R. Silk Sericin-Polylactide Protein-Polymer Conjugates as Biodegradable Amphiphilic Materials and Their Application in Drug Release Systems. *Bioconjug Chem.* 2020;31(10):2312-24. Epub 2020/09/16. doi: 10.1021/acs.bioconjchem.0c00399. PubMed PMID: 32927943.
54. Radu IC, Zaharia C, Hudita A, Tanasa E, Ginghina O, Marin M, Galateanu B, Costache M. In Vitro Interaction of Doxorubicin-Loaded Silk Sericin Nanocarriers with MCF-7 Breast Cancer Cells Leads to DNA Damage. *Polymers (Basel).* 2021;13(13):2047. Epub 2021/07/03. doi: 10.3390/polym13132047. PubMed PMID: 34206674; PMCID: PMC8271558.
55. Baker A, Wahid I, Hassan Baig M, Alotaibi SS, Khalid M, Uddin I, Dong JJ, Khan MS. Silk Cocoon-Derived Protein Bioinspired Gold Nanoparticles as a Formidable Anticancer Agent. *J Biomed Nanotechnol.* 2021;17(4):615-26. Epub 2022/01/22. doi: 10.1166/jbn.2021.3053. PubMed PMID: 35057888.
56. Asapur P, Mahapatra SK, Banerjee I. Secondary structural analysis of non-mulberry silk fibroin nanoparticles synthesized by using microwave and acetone method. *J Biomol Struct Dyn.* 2022;40(9):4100-9. Epub 2020/12/05. doi: 10.1080/07391102.2020.1852970. PubMed PMID: 33272099.
57. Baruah RR, Chandra Kalita M, Devi D. Novel non-mulberry silk fibroin nanoparticles with enhanced activity as potential candidate in nanocarrier mediated delivery system. *RSC Adv.* 2020;10(15):9070-8. Epub 2020/03/03. doi: 10.1039/c9ra08901b. PubMed PMID: 35496565; PMCID: PMC9050130.
58. Liu X, Luo H, Niu L, Feng Y, Pan P, Yang J, Li M. Cleavable poly(ethylene glycol) branched chain-modified *Antheraea pernyi* silk fibroin as a gene delivery carrier. *Nanomedicine (London, England).* 2021;16(10):839-53. Epub 2021/04/24. doi: 10.2217/nnm-2020-0481. PubMed PMID: 33890489.

59. Nayak D, Thathapudi NC, Ashe S, Nayak B. Bioengineered ethosomes encapsulating AgNPs and Tasar silk sericin proteins for non melanoma skin carcinoma (NMSC) as an alternative therapeutics. *Int J Pharm.* 2021;596:120265. Epub 2021/01/25. doi: 10.1016/j.ijpharm.2021.120265. PubMed PMID: 33486031.
60. Goswami A, Goswami N, Bhattacharya A, Borah P, Devi D. Composition and in silico structural analysis of fibroin from liquid silk of non-mulberry silkworm *Antheraea assamensis*. *Int J Biol Macromol.* 2020;163:1947-58. Epub 2020/09/11. doi: 10.1016/j.ijbiomac.2020.08.232. PubMed PMID: 32910960.
61. Gupta AK, Mita K, Arunkumar KP, Nagaraju J. Molecular architecture of silk fibroin of Indian golden silkworm, *Antheraea assama*. *Sci Rep.* 2015;5(1):12706. Epub 2015/08/04. doi: 10.1038/srep12706. PubMed PMID: 26235912; PMCID: PMC4522600.
62. Huang W, Rollett A, Kaplan DL. Silk-elastin-like protein biomaterials for the controlled delivery of therapeutics. *Expert Opin Drug Deliv.* 2015;12(5):779-91. Epub 2014/12/06. doi: 10.1517/17425247.2015.989830. PubMed PMID: 25476201; PMCID: PMC4579323.
63. Bowen CH, Dai B, Sargent CJ, Bai W, Ladiwala P, Feng H, Huang W, Kaplan DL, Galazka JM, Zhang F. Recombinant Spidroins Fully Replicate Primary Mechanical Properties of Natural Spider Silk. *Biomacromolecules.* 2018;19(9):3853-60. Epub 2018/08/07. doi: 10.1021/acs.biomac.8b00980. PubMed PMID: 30080972.
64. Yu J, Guo Y, Gu Y, Fan X, Li F, Song H, Nian R, Liu W. A novel silk fibroin protein-based fusion system for enhancing the expression of nanobodies in *Escherichia coli*. *Appl Microbiol Biotechnol.* 2022;106(5-6):1967-77. Epub 2022/03/05. doi: 10.1007/s00253-022-11857-7. PubMed PMID: 35243528; PMCID: PMC8894094.
65. Tamura T, Thibert C, Royer C, Kanda T, Abraham E, Kamba M, Komoto N, Thomas JL, Mauchamp B, Chavancy G, Shirk P, Fraser M, Prudhomme JC, Couple P. Germline transformation of the silkworm *Bombyx mori* L. using a *piggyBac* transposon-derived vector. *Nature Biotechnology.* 2000;18(5):559-. PubMed PMID: ISI:000087017500035.
66. Tomita M, Munetsuna H, Sato T, Adachi T, Hino R, Hayashi M, Shimizu K, Nakamura N, Tamura T, Yoshizato K. Transgenic silkworms produce recombinant human type III procollagen in cocoons. *Nat Biotechnol.* 2003;21(1):52-6. Epub 2002/12/17. doi: 10.1038/nbt771. PubMed PMID: 12483223.
67. Xu H, O'Brochta DA. Advanced technologies for genetically manipulating the silkworm *Bombyx mori*, a model Lepidopteran insect. *Proc Biol Sci.* 2015;282(1810):20150487: 1-8. Epub 2015/06/26. doi: 10.1098/rspb.2015.0487. PubMed PMID: 26108630; PMCID: PMC4590473.
68. Saviane A, Romoli O, Bozzato A, Freddi G, Cappelletti C, Rosini E, Cappellozza S, Tettamanti G, Sandrelli F. Intrinsic antimicrobial properties of silk spun by genetically modified silkworm strains. *Transgenic Res.* 2018;27(1):87-101. Epub 2018/02/13. doi: 10.1007/s11248-018-0059-0. PubMed PMID: 29435708.
69. Baci GM, Cucu AA, Giurgiu AI, Musca AS, Bagameri L, Moise AR, Bobis O, Ratiu AC, Dezmirean DS. Advances in Editing Silkworms (*Bombyx mori*) Genome by Using the CRISPR-Cas System. *Insects.* 2021;13(1). Epub 2022/01/22. doi: 10.3390/insects13010028. PubMed PMID: 35055871; PMCID: PMC8777690.

70. Baci GM, Moise AR, Dezmiorean DS. Utilization of Transgenic *Bombyx mori* for Biomaterials Production. *Scientific Papers: Animal Science & Biotechnologies/Lucrari Stiintifice: Zootehnie si Biotehnologii*. 2021;54(1).
71. Zhong B, Wei H, Zhuang L. Advances in research of silk gland bioreactor of piggyBac-mediated transgenic silkworm. *Scientia Agricultura Sinica*. 2011;44(21):4488-98.
72. Babb PL, Lahens NF, Correa-Garhwal SM, Nicholson DN, Kim EJ, Hogenesch JB, Kuntner M, Higgins L, Hayashi CY, Agnarsson I, Voight BF. The *Nephila clavipes* genome highlights the diversity of spider silk genes and their complex expression. *Nat Genet*. 2017;49(6):895-903. Epub 2017/05/02. doi: 10.1038/ng.3852. PubMed PMID: 28459453.
73. Kiseleva AP, Krivoschapkin PV, Krivoschapkina EF. Recent Advances in Development of Functional Spider Silk-Based Hybrid Materials. *Front Chem*. 2020;8:554. Epub 2020/07/23. doi: 10.3389/fchem.2020.00554. PubMed PMID: 32695749; PMCID: PMC7338834.
74. Weiss ACG, Herold HM, Lentz S, Faria M, Besford QA, Ang CS, Caruso F, Scheibel T. Surface Modification of Spider Silk Particles to Direct Biomolecular Corona Formation. *ACS Appl Mater Interfaces*. 2020;12(22):24635-43. Epub 2020/05/06. doi: 10.1021/acsami.0c06344. PubMed PMID: 32369330.
75. Herold HM, Dobl A, Wohlrab S, Humenik M, Scheibel T. Designed Spider Silk-Based Drug Carrier for Redox- or pH-Triggered Drug Release. *Biomacromolecules*. 2020;21(12):4904-12. Epub 2020/12/01. doi: 10.1021/acs.biomac.0c01138. PubMed PMID: 33249826.
76. Ramezaniaghdam M, Nahdi ND, Reski R. Recombinant Spider Silk: Promises and Bottlenecks. *Front Bioeng Biotechnol*. 2022;10:835637. Epub 2022/03/31. doi: 10.3389/fbioe.2022.835637. PubMed PMID: 35350182; PMCID: PMC8957953.
77. Florczak A, Mackiewicz A, Dams-Kozłowska H. Functionalized spider silk spheres as drug carriers for targeted cancer therapy. *Biomacromolecules*. 2014;15(8):2971-81. Epub 2014/06/26. doi: 10.1021/bm500591p. PubMed PMID: 24963985.
78. Florczak A, Deptuch T, Lewandowska A, Penderecka K, Kramer E, Marszałek A, Mackiewicz A, Dams-Kozłowska H. Functionalized silk spheres selectively and effectively deliver a cytotoxic drug to targeted cancer cells in vivo. *J Nanobiotechnology*. 2020;18(1):177. Epub 2020/12/03. doi: 10.1186/s12951-020-00734-y. PubMed PMID: 33261651; PMCID: PMC7709326.
79. Deptuch T, Florczak A, Lewandowska A, Leporowska E, Penderecka K, Marszałek A, Mackiewicz A, Dams-Kozłowska H. MS1-type bioengineered spider silk nanoparticles do not exhibit toxicity in an in vivo mouse model. *Nanomedicine (London, England)*. 2021;16(18):1553-65. Epub 2021/06/25. doi: 10.2217/nnm-2021-0029. PubMed PMID: 34165326.
80. Gani MNA, Ghosh MK. Impact of climate change on agriculture and sericulture2018.
81. Shilpa M, Gowda DM, Ramesh BS, Avinash G. Assessment of the impact of climatic parameters on silk cocoon production2021.

82. Long D, Xiao B, Merlin D. Genetically modified silk fibroin nanoparticles for drug delivery: preparation strategies and application prospects. *Nanomedicine (London, England)*. 2020;15(18):1739-42. Epub 2020/07/18. doi: 10.2217/nnm-2020-0182. PubMed PMID: 32677500.
83. Sato M, Kojima K, Sakuma C, Murakami M, Aratani E, Takenouchi T, Tamada Y, Kitani H. Production of scFv-conjugated affinity silk powder by transgenic silkworm technology. *PLoS One*. 2012;7(4):e34632. Epub 2012/04/13. doi: 10.1371/journal.pone.0034632. PubMed PMID: 22496833; PMCID: PMC3319607.
84. Silk Protein Microparticle-based Filler for Injection Augmentation.  
<https://ClinicalTrials.gov/show/NCT03790956>.
85. Crivelli B, Bari E, Perteghella S, Catenacci L, Sorrenti M, Mocchi M, Farago S, Tripodo G, Prina-Mello A, Torre ML. Silk fibroin nanoparticles for celecoxib and curcumin delivery: ROS-scavenging and anti-inflammatory activities in an in vitro model of osteoarthritis. *European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV*. 2019;137:37-45. Epub 2019/02/18. doi: 10.1016/j.ejpb.2019.02.008. PubMed PMID: 30772432.
86. Ghalei S, Mondal A, Hopkins S, Singha P, Devine R, Handa H. Silk Nanoparticles: A Natural Polymeric Platform for Nitric Oxide Delivery in Biomedical Applications. *ACS Appl Mater Interfaces*. 2020;12(48):53615-23. Epub 2020/11/19. doi: 10.1021/acsami.0c13813. PubMed PMID: 33205962.
87. Hudita A, Radu IC, Zaharia C, Ion AC, Ginghina O, Galateanu B, Marutescu L, Grama F, Tsatsakis A, Gurevich L, Costache M. Bio- and Hemo-Compatible Silk Fibroin PEGylated Nanocarriers for 5-Fluorouracil Chemotherapy in Colorectal Cancer: In Vitro Studies. *Pharmaceutics*. 2021;13(5):755. Epub 2021/06/03. doi: 10.3390/pharmaceutics13050755. PubMed PMID: 34069731; PMCID: PMC8160811.
88. Moin A, Wani SUD, Osmani RA, Abu Lila AS, Khafagy ES, Arab HH, Gangadharappa HV, Allam AN. Formulation, characterization, and cellular toxicity assessment of tamoxifen-loaded silk fibroin nanoparticles in breast cancer. *Drug Deliv*. 2021;28(1):1626-36. Epub 2021/07/31. doi: 10.1080/10717544.2021.1958106. PubMed PMID: 34328806; PMCID: PMC8330732.
89. Niu L, Chen G, Feng Y, Liu X, Pan P, Huang L, Guo Y, Li M. Polyethylenimine-Modified Bombyx mori Silk Fibroin as a Delivery Carrier of the ING4-IL-24 Coexpression Plasmid. *Polymers (Basel)*. 2021;13(20):3592. Epub 2021/10/24. doi: 10.3390/polym13203592. PubMed PMID: 34685354; PMCID: PMC8538240.
90. Suyamud C, Phetdee C, Jaimalai T, Prangkio P. Silk Fibroin-Coated Liposomes as Biomimetic Nanocarrier for Long-Term Release Delivery System in Cancer Therapy. *Molecules*. 2021;26(16):4936. Epub 2021/08/28. doi: 10.3390/molecules26164936. PubMed PMID: 34443524; PMCID: PMC8398433.
91. Wang T, Li Y, Liu J, Fang Y, Guo W, Liu Y, Li X, Li G, Wang X, Zheng Z, Wang X, Kaplan DL. Intraarticularly injectable silk hydrogel microspheres with enhanced mechanical and structural stability to attenuate osteoarthritis. *Biomaterials*. 2022;286:121611. Epub 2022/06/07. doi: 10.1016/j.biomaterials.2022.121611. PubMed PMID: 35660867.
92. Zhang H, Lai L, Wang Y, Ye B, Deng S, Ding A, Teng L, Qiu L, Chen J. Silk Fibroin for CpG Oligodeoxynucleotide Delivery. *ACS Biomater Sci Eng*. 2019;5(11):6082-8. Epub 2019/11/11. doi: 10.1021/acsbomaterials.9b01413. PubMed PMID: 33405662.

93. Mulinti P, Shreffler J, Hasan R, Dea M, Brooks AE. Infection Responsive Smart Delivery of Antibiotics Using Recombinant Spider Silk Nanospheres. *Pharmaceutics*. 2021;13(9):1358. Epub 2021/09/29. doi: 10.3390/pharmaceutics13091358. PubMed PMID: 34575434; PMCID: PMC8467577.